checkAd

EQS-News BriaCell’s Lead Candidate Bria-IMT Shows Promising Results For Advanced Breast Cancer Patients

EQS-News: BriaCell Therapeutics Corp.
BriaCell’s Lead Candidate Bria-IMT Shows Promising Results For Advanced Breast Cancer Patients

02.12.2022 / 16:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs like SPDR S&P Biotech (NYSEARCA: XBI) (“XBI”) and iShares Biotechnology (NASDAQ: IBB) (“IBB”) are bringing a lot of awareness and attention to the field for investors to get excited about.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) presented positive initial efficacy data in its 2021-2022 cohort of 12 advanced breast cancer patients for its clinical study of Bria-IMT immunotherapy treatment during the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Breast cancer is still one of the deadliest cancers globally. Each year in the U.S. there are about 264,000 new diagnoses and about 42,000 women and 500 men die each year from breast cancer. The average risk that a woman will develop breast cancer sometime in her lifetime is around 13%. For certain populations that risk is higher; breast cancer is the number one cause of cancer death for Hispanic women.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. BriaCell’s lead candidate Bria-IMT is marketed as an off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors. The targeted patients are advanced breast cancer patients or terminal breast cancer patients.

The Bria-IMT study showed disease control, tumor shrinkage, and potential survival benefits among 12 patients in Phase I/IIa when in combination with Incyte’s retifanlimab. 70% of patients showed either disease control or progression-free survival benefits compared with their previous therapy attempts.

Prior to the BriaCell study, the 12 patients had each failed at least 2 previous attempts at therapy regimens like chemotherapy or “targeted” therapy. The Bria-IMT clinical success is arguably even more impressive with this in mind.

Seite 1 von 2




0 Kommentare
Nachrichtenquelle: EQS Group AG
 |  103   |   |   

Schreibe Deinen Kommentar

Disclaimer

EQS-News BriaCell’s Lead Candidate Bria-IMT Shows Promising Results For Advanced Breast Cancer Patients EQS-News: BriaCell Therapeutics Corp. BriaCell’s Lead Candidate Bria-IMT Shows Promising Results For Advanced Breast Cancer Patients 02.12.2022 / 16:00 CET/CEST The issuer is solely responsible for the content of this announcement. The world of …

Nachrichten des Autors

440 Leser
388 Leser
344 Leser
308 Leser
280 Leser
240 Leser
240 Leser
228 Leser
208 Leser
204 Leser
1396 Leser
640 Leser
508 Leser
484 Leser
440 Leser
428 Leser
388 Leser
368 Leser
364 Leser
360 Leser
2476 Leser
1616 Leser
1396 Leser
1280 Leser
1068 Leser
1064 Leser
1060 Leser
960 Leser
832 Leser
820 Leser
2476 Leser
2405 Leser
2343 Leser
2225 Leser
2172 Leser
2115 Leser
2037 Leser
1861 Leser
1717 Leser
1705 Leser